Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Antibody Treatments for COVID-19 Face Challenges in the U.S.
FDA revoked EUA for many COVID-19 antibody treatments due to inefficacy against Omicron, impacting sales. Vir Biotechnology and GlaxoSmithKline's sotrovimab, Eli Lilly's bamlanivimab and etesevimab, and Regeneron's REGEN-COV affected. Lilly's bebtelovimab, effective against Omicron, received EUA. Companies are adapting to new variants.
Your Edge In Biotech
The urgent care facility at MGH Chelsea is overwhelmed with COVID-19 cases, setting records for patient visits and positive test rates. Despite high vaccination rates, the Omicron variant's transmissibility and partial immunity evasion are concerning. However, vaccinated patients generally experience milder symptoms, reducing severe outcomes. The healthcare system faces strain, but vaccines and improved treatment protocols offer hope. The community's high vaccination rate is a key factor in mitigating severe illness and death.
Anti COVID-19 drug authorized in US for those uneligible for vaccination
The FDA authorized AstraZeneca's Evusheld, a COVID-19 treatment combining tixagevimab and cilgavimab, for unvaccinated individuals aged 12+ with medical constraints. It's not a vaccine substitute, effective for six months pre-exposure, and reduces COVID-19 risk by 77%. Side effects include allergic reactions and fatigue.
J&J's new cancer drug leads a growing pipeline of dual-targeting treatments
The FDA approved Johnson & Johnson's Rybrevant, a bispecific antibody for treating a specific mutation in non-small cell lung cancer. Bispecific antibodies, targeting two proteins simultaneously, are emerging as a promising treatment for various cancers, including lymphoma, leukemia, and multiple myeloma, with several drugs in advanced clinical trials.
MAIA Biotechnology Partners with Regeneron for Phase 1/2 Trial Evaluating THIO Followed by Libtayo in Advanced NSCLC Patients
MAIA Biotechnology partners with Regeneron for a Phase 1/2 trial evaluating THIO followed by Libtayo in advanced NSCLC patients. The trial aims to assess safety, efficacy, and immune system activation, potentially transforming cancer treatment by enhancing immunotherapy effectiveness.
UK Biobank launches one of the largest scientific studies
UK Biobank, with a consortium of biopharmaceutical companies, launches a large-scale study to measure 1,500 plasma proteins in 53,000 participants, enhancing proteomics research. This aims to understand genetics-disease links, support drug development, and includes SARS-CoV-2 infection impact analysis.
Gout drug Colchicine to be tested as COVID-19 treatment
Colchicine, a gout treatment, is being tested in the RECOVERY trial for COVID-19 due to its anti-inflammatory effects. The trial, led by Oxford University, aims to determine if colchicine can reduce death risk in hospitalized patients. It's part of the world's largest COVID-19 treatment trial, which previously found dexamethasone effective for severe cases.
FDA Authorizes Breakthrough Coronavirus Drug Proven to Save Lives
The FDA authorized Eli Lilly's bamlanivimab, a monoclonal antibody drug, for mild-to-moderate COVID-19 treatment. It blocks the virus from infecting cells and is most effective when administered early. Not for hospitalized patients. Administered intravenously, it aims to prevent severe complications and reduce death risk.
The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Biologic therapy, including dupilumab, mepolizumab, and omalizumab, offers new treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting T2 inflammation. These biologics show promise in improving symptoms and quality of life, with dupilumab being FDA-approved. Patient selection for biologics considers disease severity, polyp recurrence risk, and cost-effectiveness, alongside patient preferences and goals.
Related Clinical Trials:
Advancements in the co-formulation of biologic therapeutics
Biologic therapeutics, the future of medicine, promise to revolutionize disease treatment by targeting multiple sites with biologics or their combination with small molecules. Despite their potential, challenges in stability, delivery, and manufacturing persist. Advances in co-formulation strategies are crucial for their clinical application, offering enhanced therapeutic efficacy and patient compliance.
© Copyright 2025. All Rights Reserved by MedPath